VS-7375 + Cetuximab for Pancreatic Cancer

This trial investigates a new treatment called VS-7375, both alone and combined with cetuximab, to determine its safety and effectiveness for individuals with metastatic pancreatic cancer and a specific KRAS G12D mutation. The trial seeks to evaluate the efficacy of these treatments both individually and in combination. Suitable participants have a diagnosis of pancreatic cancer, possess the KRAS G12D mutation, and have received either no or limited prior treatment for their metastatic cancer. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial requires stopping certain medications before starting, such as strong CYP3A4 inhibitors/inducers and PPIs or H2 blockers. It's best to discuss your current medications with the trial team to see if any need to be paused.

Previous studies have shown that VS-7375 is safe. Participants generally tolerated doses of 400 mg and 600 mg well, with no serious side effects preventing dose escalation. When combined with cetuximab, the treatment was also well-tolerated in individuals with advanced solid tumors. The available data report no severe safety issues, suggesting that both VS-7375 alone and with cetuximab are safe for further testing in humans.¹²³⁴⁵

Unlike the standard treatments for pancreatic cancer, like chemotherapy and radiation, VS-7375 is making waves because it targets specific cancer pathways potentially leading to more precise cancer cell destruction. Researchers are especially excited about combining VS-7375 with cetuximab, an antibody that blocks growth signals in cancer cells, which could enhance treatment effectiveness. This combination therapy might offer a new hope for patients by potentially improving outcomes and reducing side effects compared to traditional therapies.

Research has shown that the drug VS-7375 may help treat pancreatic cancer with a specific mutation called KRAS G12D. In an earlier study, 80% of patients experienced tumor shrinkage when using VS-7375 alone. In this trial, some participants will receive VS-7375 as monotherapy. Another study found that more than half of the patients (52%) had their tumors shrink or stop growing. In this trial, other participants will receive VS-7375 combined with cetuximab. When used with cetuximab, 41% of heavily pre-treated patients saw their tumors shrink or disappear. These results suggest that VS-7375, alone or with cetuximab, could effectively manage this type of pancreatic cancer.²⁴⁶⁷⁸